Page last updated: 2024-09-03
tak 044 and cgs 26393
tak 044 has been researched along with cgs 26393 in 1 studies
Compound Research Comparison
| Studies (tak 044) | Trials (tak 044) | Recent Studies (post-2010) (tak 044) | Studies (cgs 26393) | Trials (cgs 26393) | Recent Studies (post-2010) (cgs 26393) |
|---|---|---|---|---|---|
| 105 | 8 | 2 | 9 | 0 | 0 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Goto, K | 1 |
Reviews
1 review(s) available for tak 044 and cgs 26393
| Article | Year |
|---|---|
[Prospects for endothelin-related drugs].
Topics: Animals; Aspartic Acid Endopeptidases; Bosentan; Cardiovascular Diseases; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Hemodynamics; Humans; Metalloendopeptidases; Organophosphonates; Peptides, Cyclic; Quinazolines; Receptors, Endothelin; Sulfonamides; Sulfonylurea Compounds; Tetracyclines; Tetrazoles | 2004 |